Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, the Biomedical Advanced Research and Development Authority, the Defense Advanced Research Projects Agency, the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, the Coalition for Epidemic Preparedness Innovations, and Bill & Melinda Gates Foundation. Moderna, Inc. also has collaborations with Lonza Ltd. for the manufacture of COVID-19 vaccine; and Catalent Inc., Laboratorios Farmacéuticos Rovi, S.A., Recipharm, and Lonza Group for fill-finish manufacturing of its COVID-19 vaccine candidate, as well as Aldevron, LLC for supporting COVID-19 vaccine and additional programs in company's clinical development pipeline. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
IPO Year: 2018
Exchange: NASDAQ
Website: modernatx.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/18/2024 | Buy → Hold | Argus | |
| 12/10/2024 | $41.00 | Underperform | BofA Securities |
| 11/19/2024 | $42.00 | Hold | Berenberg |
| 11/18/2024 | $58.00 | Hold → Buy | HSBC Securities |
| 11/15/2024 | $40.00 | Underperform | Wolfe Research |
| 10/17/2024 | $55.00 | Mkt Perform | Bernstein |
| 9/13/2024 | $120.00 → $65.00 | Buy → Hold | Jefferies |
| 9/13/2024 | $88.00 → $70.00 | Neutral → Underweight | JP Morgan |
| 9/13/2024 | Outperform → Perform | Oppenheimer | |
| 8/28/2024 | $82.00 | Reduce → Hold | HSBC Securities |
CAMBRIDGE, MA / ACCESS Newswire / January 17, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced ongoing support from the U.S. Department of Health and Human Services (HHS) to accelerate the development of mRNA-based pandemic influenza vaccines. The award was made through the Rapid Response Partnership Vehicle (RRPV) Consortium with funding from the Biomedical Advanced Research and Development Authority (BARDA), part of the HHS Administration for Strategic Preparedness and Response (ASPR).The project will provide additional support for late-stage development and licensure of pre-pandemic mRNA-based vaccines. The agreement will also support the expansion of clinical studies for up to five add
Achieved 2024 product sales of $3.0 to 3.1 billion (unaudited) and an ending cash balance of approximately $9.5 billion (unaudited)Updates 2025 expected revenue range to $1.5 to 2.5 billionExpects to reduce 2025 cash cost expenses by $1.0 billion with a plan for additional 2026 cost reductions of $0.5 billionUpdates 2025 expected ending cash balance to approximately $6.0 billionAnticipates milestones across 10 prioritized programs, including up to three potential 2025 approvals and six registrational data readouts CAMBRIDGE, MA / ACCESSWIRE / January 13, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced business updates and progress across its pipeline of mRNA medicines. Moderna enters 2025
NEW YORK, Dec. 13, 2024 (GLOBE NEWSWIRE) -- Nasdaq (NASDAQ:NDAQ) today announced the results of the annual reconstitution of the Nasdaq-100 Index® (NASDAQ:NDX), which will become effective prior to market open on Monday, December 23, 2024. The following three companies will be added to the Index: Palantir Technologies Inc. (NASDAQ:PLTR), MicroStrategy Incorporated (NASDAQ:MSTR), and Axon Enterprise, Inc. (NASDAQ:AXON). The Nasdaq-100 Index® is composed of 100 of the largest non-financial companies1 listed on The Nasdaq Stock Market® and dates to January 1985 – nearly 40 years ago –when it was launched along with the Nasdaq Financial-100™ Index, which is comprised of 100 of the largest fi
Resources realigned to focus primarily on in vivo macrophage engineering platform for fibrosis, oncology and autoimmune disease therapies Development of CT-0525 to be discontinued; workforce reduced by 34% PHILADELPHIA, Dec. 9, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a leader in macrophage-focused therapeutics, today announced a strategic reprioritization of its pipeline, cessation of development of CT-0525, and a reduction in the workforce by 34%. These measures will enable Carisma to focus its resources on advancing its in vivo macrophage engineering platform for the development of fibrosis, oncology and autoimmune disease therapies. Thi
CAMBRIDGE, MA / ACCESSWIRE / November 25, 2024 / Moderna, Inc. (NASDAQ:MRNA), today announced its participation in the following upcoming investor conferences:7th Annual Evercore ISI HealthCONx Conference, on Wednesday, December 4th at 1:20pm ETPiper Sandler 36th Annual Healthcare Conference, on Thursday, December 5th at 10:30am ETA live webcast of each of these presentations will be available under "Events and Presentations" in the Investors section of the Moderna website at investors.modernatx.com. A replay of each webcast will be archived on Moderna's website for at least 30 days following the presentation.About ModernaModerna is a leader in the creation of the field of mRNA medicine. Thr
CAMBRIDGE, Mass., Nov. 20, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Metaphore Biotechnologies, a Flagship-founded biotechnology company designing novel therapeutics by combining machine learning and molecular mimicry, today announced that Angela Hwang, MBA, will join Flagship Pioneering as CEO-Partner, and Metaphore as Chief Executive Officer, effective January 1, 2025. Most recently, Hwang served as Chief Commercial Officer and President of the Global Biopharmaceuticals Business at Pfizer. During her tenure at Pfizer, Hwang helped brin
Ampersand's AND™ Platform will be used to identify programmed biologics for the treatment of obesity-related targets Montai's CONECTA™ AI platform will be used to identify small molecules directed to a potential Non-Small Cell Lung Cancer-related target Collaborations will leverage Pfizer's deep expertise in early discovery and development for cardiometabolic and cancer treatments, two priority therapeutic areas for the company CAMBRIDGE, Mass., Nov. 20, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today announced Ampersand Biomedicines and Montai Therapeutics have entered into agreements to identify targeted molecules that could potentially be further dev
Williams was promoted from Operating Partner at Flagship Pioneering and President at Apriori Bio Apriori Bio has made significant progress in 2024, including securing a collaboration with CEPI, assembling a world class board of directors and building out an early pipeline of prospective vaccines CAMBRIDGE, Mass., Nov. 13, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Apriori Bio, a biotechnology company aimed at providing humanity with variant-resilient protection against rapidly-evolving viruses, today announced that Craig Williams, MBA, has been promoted to CEO-Partner at Flagship Pioneering and Chief Executive Officer of Apriori.
Valo Elevates Brett Blackman to Chief Operating Officer and Appoints Travis Wilson to its Board of Directors CAMBRIDGE, Mass., Nov. 13, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Valo Health today announced that industry leader Brian M. Alexander, M.D., M.P.H. has been appointed Chief Executive Officer of Valo Health and CEO-Partner of Flagship Pioneering. Dr. Alexander brings two decades of biotechnology, biopharma, and medical leadership, most recently as SVP, Research & Development and Head of Boston Roche Innovation Center (BRIC), for Roche/Genentech and previously as CEO of Foundation Medicine. Valo also announced the appointments of Brett Blackman
CAMBRIDGE, MA / ACCESSWIRE / November 12, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced it was ranked the number one large employer in BioSpace's 2025 Best Places to Work report based on the Company's reputation and commitment to innovation."We are honored to be recognized by BioSpace as the most desirable large employer in the life sciences industry for the fourth year in a row," said Stéphane Bancel, Chief Executive Officer of Moderna. "I am proud of the company we are building and the investments we have made in our team. We remain focused on creating an environment where employees can have meaningful careers, and where curiosity, purpose and innovation drive our mission for patients
8-K - Moderna, Inc. (0001682852) (Filer)
10-Q - Moderna, Inc. (0001682852) (Filer)
8-K - Moderna, Inc. (0001682852) (Filer)
8-K - Moderna, Inc. (0001682852) (Filer)
8-K - Moderna, Inc. (0001682852) (Filer)
10-Q - Moderna, Inc. (0001682852) (Filer)
8-K - Moderna, Inc. (0001682852) (Filer)
144 - Moderna, Inc. (0001682852) (Subject)
144 - Moderna, Inc. (0001682852) (Subject)
8-K - Moderna, Inc. (0001682852) (Filer)
Reports third quarter revenues of $1.9 billion, GAAP net income of $13 million and GAAP EPS of $0.03Achieves year-to-date product sales of $2.2 billion; reiterates 2024 expected product sales of $3.0 to $3.5 billionInitiated dosing in two pivotal Phase 3 trials to assess efficacy of investigational mRNA vaccines against norovirus and influenzaAnnounces expansion of its Executive Committee CAMBRIDGE, MA / ACCESSWIRE / November 7, 2024 / Moderna, Inc. (NASDAQ:MRNA) today reported financial results and provided business updates for the third quarter of 2024."During the third quarter, we focused on execution with the launch of our updated COVID-19 and RSV vaccines in markets across the globe. I
CAMBRIDGE, MA / ACCESSWIRE / October 17, 2024 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, November 7, 2024 to report its third quarter 2024 financial results, and provide a corporate update.A live webcast of the call will be available under "Events and Presentations" in the Investors section of the Moderna website.Webcast: https://investors.modernatx.comThe archived webcast will be available on Moderna's website approximately two hours after the conference call and will be available for one year following the call.About ModernaModerna is a leader in the creation of the field of mRNA medicine. Through the adv
Reports second quarter revenues of $241 million, GAAP net loss of $1.3 billion and GAAP EPS of $(3.33)Updates 2024 financial framework and revises expectations for product sales to $3.0 to $3.5 billionReceived U.S. FDA approval for RSV vaccine, mRESVIA, and began shipping in July; received EMA positive opinion in JuneAnnounced positive Phase 3 data for combination vaccine against influenza and COVID-19Announced positive Phase 3 data for next-generation COVID-19 vaccine CAMBRIDGE, MA / ACCESSWIRE / August 1, 2024 / Moderna, Inc. (NASDAQ:MRNA) today reported financial results and provided business updates for the second quarter of 2024."During the second quarter, we marked the approval of our
CAMBRIDGE, MA / ACCESSWIRE / July 10, 2024 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, August 1, 2024 to report its second quarter 2024 financial results, and provide a corporate update.A live webcast of the call will be available under "Events and Presentations" in the Investors section of the Moderna website.Webcast: https://investors.modernatx.comThe archived webcast will be available on Moderna's website approximately two hours after the conference call and will be available for one year following the call.About ModernaModerna is a leader in the creation of the field of mRNA medicine. Through the advance
Reports first quarter revenues of $167 million, GAAP net loss of $1.2 billion and GAAP diluted EPS of $(3.07)Prepares for launches of RSV vaccine and Spikevax® 2024-2025 formula; reaffirms 2024 expected product sales of approximately $4 billionInitiated three new clinical studies evaluating Moderna's investigational individualized neoantigen therapy in combination with Merck's Keytruda® for treatment of patients with bladder cancer, kidney cancer and cutaneous squamous cell carcinomaAdvanced three new vaccine programs (Epstein-Barr virus, Varicella-Zoster virus, norovirus) toward Phase 3 clinical trials as announced at Vaccines Day investor eventCAMBRIDGE, MA / ACCESSWIRE / May 2, 2024 / Mod
CAMBRIDGE, MA / ACCESSWIRE / April 17, 2024 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, May 2, 2024 to report its first quarter 2024 financial results, and provide a corporate update.A live webcast of the call will be available under "Events and Presentations" in the Investors section of the Moderna website.Webcast: https://investors.modernatx.comThe archived webcast will be available on Moderna's website approximately two hours after the conference call and will be available for one year following the call.About ModernaModerna is a leader in the creation of the field of mRNA medicine. Through the advancemen
Posts fourth quarter revenues of $2.8 billion, GAAP net income of $217 million and GAAP diluted EPS of $0.55Reports full-year revenues of $6.8 billion, GAAP net loss of $(4.7) billion and GAAP diluted EPS of $(12.33); loss primarily driven by mostly non-cash charges of $3.7 billion related to resizing and a tax valuation allowanceReaffirms 2024 expected product sales of approximately $4 billionExpects regulatory approvals for its investigational RSV vaccine for older adults beginning in first half of 2024, and anticipates additional key milestones from its late-stage pipeline this yearCAMBRIDGE, MA / ACCESSWIRE / February 22, 2024 / Moderna, Inc. (NASDAQ:MRNA) today reported financial result
CAMBRIDGE, MA / ACCESSWIRE / February 1, 2024 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, February 22, 2024 to report its fourth quarter and full year 2023 financial results, and provide a corporate update.A live webcast of the call will be available under "Events and Presentations" in the Investors section of the Moderna website.Webcast: https://investors.modernatx.comThe archived webcast will be available on Moderna's website approximately two hours after the conference call and will be available for one year following the call.About ModernaModerna is a leader in the creation of the field of mRNA medicine.
Third quarter 2023 revenues of $1.8 billion; Company expects 2023 revenues of at least $6 billionSpikevax U.S. market share to date increased to 45% from 36% in 2022Company anticipates 2024 revenue of approximately $4 billion and return to growth in 2025Company has significantly improved future cost of sales by resizing its manufacturing capacity, contributing to a third quarter net loss of $3.6 billion, primarily driven by mostly non-cash charges of $3.1 billion related to resizing and a tax valuation allowanceCompany's late-stage pipeline has six Phase 3 programsCompany expects to break even in 2026 through product launches and disciplined investmentCAMBRIDGE, MA / ACCESSWIRE / November 2,
CAMBRIDGE, MA / ACCESSWIRE / October 12, 2023 / Moderna, Inc. (NASDAQ:MRNA) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, November 2, 2023 to report its third quarter 2023 financial results, and provide a corporate update.A live webcast of the call will be available under "Events and Presentations" in the Investors section of the Moderna website.Webcast: https://investors.modernatx.comThe archived webcast will be available on Moderna's website approximately two hours after the conference call and will be available for one year following the call.About ModernaIn over 10 years since its inception, Moderna has transformed from a research-stage
4 - Moderna, Inc. (0001682852) (Issuer)
4 - Moderna, Inc. (0001682852) (Issuer)
4 - Moderna, Inc. (0001682852) (Issuer)
4 - Moderna, Inc. (0001682852) (Issuer)
4 - Moderna, Inc. (0001682852) (Issuer)
4 - Moderna, Inc. (0001682852) (Issuer)
4 - Moderna, Inc. (0001682852) (Issuer)
4 - Moderna, Inc. (0001682852) (Issuer)
4 - Moderna, Inc. (0001682852) (Issuer)
4 - Moderna, Inc. (0001682852) (Issuer)
SC 13G/A - Moderna, Inc. (0001682852) (Subject)
SC 13G/A - Moderna, Inc. (0001682852) (Subject)
SC 13G/A - Moderna, Inc. (0001682852) (Subject)
SC 13G/A - Moderna, Inc. (0001682852) (Subject)
SC 13G/A - Moderna, Inc. (0001682852) (Subject)
SC 13G/A - Moderna, Inc. (0001682852) (Subject)
SC 13G/A - Moderna, Inc. (0001682852) (Subject)
SC 13G/A - Moderna, Inc. (0001682852) (Subject)
SC 13G/A - Moderna, Inc. (0001682852) (Subject)
SC 13G/A - Moderna, Inc. (0001682852) (Subject)
For Immediate Release: November 30, 2020 The U.S. Food and Drug Administration has scheduled a meeting of its Vaccines and Related Biological Products Advisory Committee (VRBPAC) on Dec. 17 to discuss the request for emergency use authorization (EUA) for a COVID-19 vaccine from Moderna, Inc. “In keeping with the FDA’s commitment to ensuring full transparency, dialogue and efficiency, the Vaccines and Related Biological Products Advisory Comm
Argus downgraded Moderna from Buy to Hold
BofA Securities resumed coverage of Moderna with a rating of Underperform and set a new price target of $41.00
Berenberg initiated coverage of Moderna with a rating of Hold and set a new price target of $42.00
HSBC Securities upgraded Moderna from Hold to Buy and set a new price target of $58.00
Wolfe Research initiated coverage of Moderna with a rating of Underperform and set a new price target of $40.00
Bernstein initiated coverage of Moderna with a rating of Mkt Perform and set a new price target of $55.00
Jefferies downgraded Moderna from Buy to Hold and set a new price target of $65.00 from $120.00 previously
JP Morgan downgraded Moderna from Neutral to Underweight and set a new price target of $70.00 from $88.00 previously
Oppenheimer downgraded Moderna from Outperform to Perform
HSBC Securities upgraded Moderna from Reduce to Hold and set a new price target of $82.00
CAMBRIDGE, Mass., Nov. 20, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Metaphore Biotechnologies, a Flagship-founded biotechnology company designing novel therapeutics by combining machine learning and molecular mimicry, today announced that Angela Hwang, MBA, will join Flagship Pioneering as CEO-Partner, and Metaphore as Chief Executive Officer, effective January 1, 2025. Most recently, Hwang served as Chief Commercial Officer and President of the Global Biopharmaceuticals Business at Pfizer. During her tenure at Pfizer, Hwang helped brin
Williams was promoted from Operating Partner at Flagship Pioneering and President at Apriori Bio Apriori Bio has made significant progress in 2024, including securing a collaboration with CEPI, assembling a world class board of directors and building out an early pipeline of prospective vaccines CAMBRIDGE, Mass., Nov. 13, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Apriori Bio, a biotechnology company aimed at providing humanity with variant-resilient protection against rapidly-evolving viruses, today announced that Craig Williams, MBA, has been promoted to CEO-Partner at Flagship Pioneering and Chief Executive Officer of Apriori.
Valo Elevates Brett Blackman to Chief Operating Officer and Appoints Travis Wilson to its Board of Directors CAMBRIDGE, Mass., Nov. 13, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Valo Health today announced that industry leader Brian M. Alexander, M.D., M.P.H. has been appointed Chief Executive Officer of Valo Health and CEO-Partner of Flagship Pioneering. Dr. Alexander brings two decades of biotechnology, biopharma, and medical leadership, most recently as SVP, Research & Development and Head of Boston Roche Innovation Center (BRIC), for Roche/Genentech and previously as CEO of Foundation Medicine. Valo also announced the appointments of Brett Blackman
CAMBRIDGE, Masss. and LONDON, Oct. 23, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today announced that Junaid Bajwa, M.D., has joined its London office as Senior Partner and Head of United Kingdom. In this role, Dr. Bajwa will play an integral role in advancing new strategic opportunities and partnerships for Flagship and its ecosystem of companies in the United Kingdom and throughout Europe. Dr. Bajwa will also serve as Science Partner for Pioneering Intelligence, Flagship's strategic initiative that is building unique AI/ML knowledge to accelerate innovation across the ecosystem.
CAMBRIDGE, Mass., Oct. 9, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today announced that Paul Parker has joined as Managing Partner, Capital Solutions and Value Realization. In this role, Parker will lead all capital solutions efforts at Flagship, driving portfolio value realization, fundraising activities, and building and managing Flagship's relationships with Limited Partners as well as strategic and financial investors. He will also play a key role on Flagship's senior leadership team, helping drive value, impact, and effectiveness across the organization.
CAMBRIDGE, Mass., Oct. 3, 2024 /PRNewswire/ -- Invaio Sciences, a Flagship Pioneering bioplatform company focused on accelerating the leap to nature-positive agriculture, today announced the appointment of André Andonian as the new Chairman of its Board of Directors. Robert Berendes has decided to step down after serving as Chairman of the Board since 2019 and will continue to serve on the board of Invaio. Andonian is Chair of Asia Pacific and Strategic Advisor at Flagship Pioneering, where he and Ignacio Martinez are responsible partners for Invaio. He is also Senior Partner
Hussain brings more than 35 years of commercial leadership and operating experience in healthcare, most recently serving as CEO of Vifor PharmaAs former Global President of GSK, Pharmaceuticals and Vaccines, Hussain brings significant global vaccine commercialization experience in emerging and mature markets, along with significant Board of Directors expertise CAMBRIDGE, MA / ACCESSWIRE / October 2, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that Abbas Hussain, former Chief Executive Officer of Vifor Pharma, has joined Moderna's Board of Directors, effective October 2, 2024."As Moderna accelerates our global commercialization efforts, Abbas is a tremendous addition to our Board," sai
Former White House Top Health Security Official to Lead Flagship's Preemptive Health and Medicine Initiative CAMBRIDGE, Mass., Aug. 6, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today announced that globally distinguished healthcare expert, entrepreneur, and public policy leader Raj Panjabi, M.D., MPH, will join Flagship as Senior Partner. Dr. Panjabi will lead Flagship's Preemptive Health and Medicine Initiative (PH&M), which is pioneering a new field to protect, maintain, or improve people's health before they get sick. In its fifth year, the initiative is grounded in the premise that health should be accessible for all and pursues interventions that prot
Chris Schade appointed as Board ChairpersonLynne Parshall, Robert Plenge, M.D., Ph.D., and Nancy Simonian, M.D., appointed to Board of DirectorsCAMBRIDGE, Mass., July 17, 2024 /PRNewswire/ -- Alltrna, a Flagship Pioneering company unlocking transfer RNA (tRNA) biology and pioneering tRNA therapeutics to regulate the protein universe and resolve disease, today announced the appointment of Chris Schade, Growth Partner at Flagship Pioneering, as Chairperson of the Board, succeeding Noubar Afeyan, Ph.D., Co-Founder of Alltrna and Founder and CEO of Flagship Pioneering. In addition, Alltrna also announced the appointments to the company's Board of Directors of Lynne Parshall, founding Chief Opera
O'Shea is a Seasoned Global Executive with more than 20 Years' Experience across the Agriculture, Food and Pharmaceutical Industries CAMBRIDGE, Mass., April 8, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Invaio Sciences, a bioplatform company accelerating the leap to nature-positive agriculture, today announced that Amy O'Shea has joined Flagship Pioneering as CEO-Partner and Invaio as Chief Executive Officer and Board Director. O'Shea is a seasoned global executive with more than 20 years' experience across the agriculture, food, and phar